Literature DB >> 7549026

The humoral immune system in coeliac disease.

M Mäki1.   

Abstract

IgA is transported into intestinal secretions to perform exclusion of luminal antigens. The prerequisites are antigen sampling by the Peyer's patch M cells, antigen processing by antigen-presenting cells, and presentation of antigenic peptides by HLA class II molecules to immunocompetent T-cells. The basis for intestinal immunity is the maturation cycle of specifically primed T and B cells from the gut-associated lymphoid tissue via mesenteric lymph nodes and peripheral blood back to the intestinal lamina propria. In coeliac disease, patients are sensitized against gluten and serum gliadin antibodies are often detected. Gliadin antibodies are also found in other gastrointestinal diseases, other disorders and in healthy individuals not carrying the coeliac disease-specific DQA/DQB alleles. On the other hand, serum reticulin and endomysium autoantibodies are both sensitive and highly disease-specific. Positivity in patients with normal jejunal morphology indicates latency of coeliac disease. These tissue autoantibodies are directed against fibroblast-derived extracellular matrix proteins. The immune system is involved in the amplification and perpetuation of the abnormalities of the intestinal mucosa in coeliac disease. The role of antibody in the pathogenesis remains unknown. The author hypothesizes gluten-triggered autoimmune mechanism to be operative.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7549026     DOI: 10.1016/0950-3528(95)90030-6

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


  26 in total

Review 1.  Celiac disease. CME update for family physicians.

Authors:  Shane M Devlin; Christopher N Andrews; Paul L Beck
Journal:  Can Fam Physician       Date:  2004-05       Impact factor: 3.275

Review 2.  Recent advances in the understanding of celiac disease: therapeutic implications for the management of pediatric patients.

Authors:  John H Kwon; Richard J Farrell
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  Dietary modifications: food dependent autoimmunity in coeliac disease.

Authors:  A M Mowat
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

Review 4.  Antibodies in celiac disease: implications beyond diagnostics.

Authors:  Sergio Caja; Markku Mäki; Katri Kaukinen; Katri Lindfors
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

Review 5.  Testing for antireticulin antibodies in patients with celiac disease is obsolete: a review of recommendations for serologic screening and the literature.

Authors:  Sarada L Nandiwada; Anne E Tebo
Journal:  Clin Vaccine Immunol       Date:  2013-01-30

6.  Prevalence of silent celiac disease in patients with autoimmune thyroiditis from Northern Sardinia.

Authors:  G F Meloni; P A Tomasi; A Bertoncelli; G Fanciulli; G Delitala; T Meloni
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

Review 7.  Role of transglutaminase 2 in celiac disease pathogenesis.

Authors:  Cornelius Klöck; Thomas R Diraimondo; Chaitan Khosla
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

8.  In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies.

Authors:  I R Korponay-Szabó; T Halttunen; Z Szalai; K Laurila; R Király; J B Kovács; L Fésüs; M Mäki
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

9.  Anti-alpha-gliadin antibodies (AGA) in the serum of coeliac children and controls recognize an identical collection of linear epitopes of alpha-gliadin.

Authors:  M ten Dam; Y Van De Wal; M L Mearin; Y Kooy; S Peña; J W Drijfhout; F Koning; M Van Tol
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

10.  Gliadin and tissue transglutaminase complexes in normal and coeliac duodenal mucosa.

Authors:  R Ciccocioppo; A Di Sabatino; C Ara; F Biagi; M Perilli; G Amicosante; M G Cifone; G R Corazza
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.